StreetInsider.com News Articles

Profusa shareholders approve acquisition and Nasdaq compliance measures

Wed, 24 Jun 2026 08:00:48 -0400

Profusa, Inc. (Nasdaq: PFSA) said its shareholders approved all proposals at the company's 2026 Annual Meeting of Shareholders held June 23, 2026, in Berkeley, California.

The approved measures include authorization for the company's planned acquisition of the PanOmics multi-omics diagnostics platform from BioInsights LLC, approval of debt conversion matters aimed at strengthening the balance sheet, and authorization for a reverse stock split if the board determines it necessary to maintain Nasdaq listing compliance.

Shareholders also approved the election of a director, an amendment to the company's equity incentive plan, and authority to adjourn the meeting if additional shareholder solicitation was needed.

"We are

Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts

Wed, 24 Jun 2026 08:00:00 -0400

BERKELEY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces that shareholders approved all proposals presented at the Company’s 2026 Annual Meeting of Shareholders held on June 23, 2026.

The approved proposals included authorization related to the Company's planned acquisition of the PanOmics™ multi-omics diagnostics platform from BioInsights LLC, approval of debt conversion-related matters intended to strengthen the Company's balance sheet, authorization for a reverse stock split if deemed necessary by the Board to support Nasdaq listing compliance efforts, the election of a director, an

Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts

Wed, 24 Jun 2026 08:00:00 -0400

Profusa submits response to European regulator for Lumee device review

Fri, 12 Jun 2026 08:00:19 -0400

Profusa Inc. (NASDAQ: PFSA) submitted a response package to European Notified Body GMED as part of the ongoing CE Mark review process for its Lumee Oxygen Platform, the company announced.

The submission follows the completion of Stage 1 and Stage 2 quality system and technical documentation assessments conducted by GMED under the Medical Device Regulation conformity assessment process. The response package included updates to technical documentation, quality system evidence, clinical evaluation activities, and supporting validation information.

"Submitting our responses to GMED marks another meaningful milestone in the CE Mark review process," said Ben Hwang, Chairman and Chief Executive Officer of Profusa. "We

Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

Fri, 12 Jun 2026 08:00:00 -0400

BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its response package to questions received from its European Notified Body, GMED, following the successful completion of the Stage 1 and Stage 2 quality system and technical documentation assessments conducted by GMED as part of the MDR conformity assessment process for the Lumee^® Oxygen Platform.

The response package included updates across multiple aspects of the MDR submission, including technical documentation, quality system evidence, clinical evaluation activities, and supporting

Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

Fri, 12 Jun 2026 08:00:00 -0400

The response package included updates across multiple aspects of the MDR submission, including technical documentation, quality system evidence, clinical evaluation activities, and supporting

Profusa urges shareholders to vote for all proposals at annual meeting

Wed, 10 Jun 2026 08:02:37 -0400

Profusa Inc. (NASDAQ: PFSA) issued a letter to shareholders encouraging support for all proposals at its June 23, 2026 annual meeting. The digital health company's board of directors unanimously recommends voting for the proposals.

Chairman and Chief Executive Officer Ben Hwang stated the proposals are intended to support the company's efforts to maintain its Nasdaq listing, enable securities issuance for the previously announced PanOmics asset acquisition, satisfy Nasdaq shareholder approval requirements for financing arrangements, and provide flexibility for equity compensation programs.

The Berkeley, California-based company announced an agreement to acquire assets relating to the PanOmics Assay platform, which it expects to expand

Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting

Wed, 10 Jun 2026 08:00:00 -0400

BERKELEY, CA, June 10, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a leading digital health company pioneering next-generation biosensing technologies, today issued the following letter from Chairman and Chief Executive Officer Ben Hwang, Ph.D., to shareholders in advance of the Company's 2026 Annual Meeting of Shareholders scheduled for June 23, 2026.

Dear Fellow Shareholders,

As we approach our 2026 Annual Meeting of Shareholders, I would like to personally thank you for your continued support of Profusa and our mission to transform healthcare through innovative diagnostic and health

Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting

Wed, 10 Jun 2026 08:00:00 -0400

Dear Fellow Shareholders,

Profusa transfers listing to Nasdaq Capital Market

Fri, 15 May 2026 07:31:43 -0400

Profusa Inc. (NASDAQ: PFSA) announced its listing transfer to the Nasdaq Capital Market, effective May 15, 2026. The digital health company develops technology for continuous monitoring of biochemistry.

The transfer represents the first step in a series of interim milestones established by the Nasdaq Hearings Panel to ensure continued compliance with bid price and stockholders' equity requirements for Capital Market listing.

Based in Berkeley, California, Profusa develops tissue-integrated sensors that detect and transmit medical-grade data. The company describes itself as being in the commercial stage and focuses on injectable biosensors and data platform technology for personal and medical applications.

The company stated the

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Fri, 15 May 2026 07:30:00 -0400

BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces that, effective May 15, 2026, the Company will now be listed on The Nasdaq Capital Market.

The move is the first of a previously announced series of interim milestones as laid out by the Nasdaq Hearings Panel to ensure continued compliance with the bid price and stockholders’ equity requirements for continued listing on the Capital Market tier.

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Fri, 15 May 2026 07:30:00 -0400

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Fri, 15 May 2026 07:30:00 -0400

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Fri, 15 May 2026 07:30:00 -0400

Peter O'Rourke joins Quantum Cyber board as independent director

Thu, 14 May 2026 08:02:55 -0400